Clinical Perspective on Use of Long-Read Sequencing in Prenatal Diagnosis of Thalassemia
Clinical Chemistry · 2023
DOI: 10.1093/clinchem/hvac223 ↗Kurz gefasst
Editorial in der Zeitschrift Clinical Chemistry, 2023. Verfasst von Diana M Toledo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Genomics Platform, The Broad Institute of MIT and Harvard, Cambridge, MA, USA. Hauptthemen laut MEDLINE: alpha-Thalassemia, beta-Thalassemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
This is an editorial focusing on the clinical perspective of a long-read sequencing method in the prenatal diagnosis of alpha- and beta-thalassemia, including a comparison between this method and standard PCR-based methods. Though incremental, the increased sensitivity and specificity using long-read sequencing is an important advantage of this methodology in the prenatal diagnostic arena due to false positive or false negative results having greater consequence when a family is making decisions about their pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genomics Platform, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Zitieren
APA
Toledo, D. M., & Lafferty, K. A. (2023). Clinical Perspective on Use of Long-Read Sequencing in Prenatal Diagnosis of Thalassemia. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvac223
Vancouver
Toledo DM, Lafferty KA. Clinical Perspective on Use of Long-Read Sequencing in Prenatal Diagnosis of Thalassemia. Clinical Chemistry. 2023. doi:10.1093/clinchem/hvac223
BibTeX
@article{Toledo2023,
author = {Toledo, Diana M and Lafferty, Katherine A},
title = {Clinical Perspective on Use of Long-Read Sequencing in Prenatal Diagnosis of Thalassemia},
journal = {Clinical Chemistry},
year = {2023},
doi = {10.1093/clinchem/hvac223}
}
EUVIMED